摘要
目的比较培美曲塞或多西他赛联合顺铂治疗晚期非小细胞肺癌的疗效及不良反应方法68例晚期非小细胞肺癌患者被分入培美曲塞组和多西他赛组。31例接受培美曲塞500 mg/m^2,第1天;顺铂75 mg/m^2,第1天。37例接受多西他赛75 mg/m^2,第1天;顺铂75 mg/m^2,第1天。入选患者至少接受2个周期以上化疗,主要评价指标:近期疗效及化疗后的不良反应。结果培美曲塞组及多西他赛组的治疗有效率分别是41.9%和36.7%(P>0.05)。培美曲塞组和多西他赛组患者的中位生存时间分别为9.2和8.3个月,1年生存率分别为29.0%和24.3%(P>0.05)。两组的不良反应主要为骨髓抑制、恶心/呕吐、乏力及脱发。培美曲塞组中性粒细胞减少的发生率明显低于多西他赛组(25.8%vs 51.4%,P<0.05)。结论对于晚期非小细胞肺癌患者,使用培美曲塞或多西他赛联合顺铂进行化疗疗效相似,但培美曲塞联合顺铂不良反应相对较小,可以作为一线治疗方案使用。
Objective To compare tile efficaey and safety of pemetrexed and docetaxel plus eisplatin in treatment of patients with advanced non - small - cell lung cancer（NSCI,C）. Methods Sixty - eight patients with advanced NSCLC who had a performance status of 0 to 2 were assigned to two groups（ pemetrexed group and docetaxel group）. 31 patients received pemetrexed 500 mg/m^2 plus cispaltiu 75 mg/m^2 while the rest received docetaxel 75 mg/m^2 plus cispaltin 75 mg/m^2. All patients received a minimum of two eourses of chemotherapy. Results The overall response rate was 41.9% vs 36.7% , （ P 〉 0. 05） and median survival time was 9.2 months vs 8.3 mnnths in pemetrexed and doeetaxel groups, respectively. The 1 - year survival rate in pemetrexed and docetaxel gronps was 29.0% and 24. 3% （P 〉 0.05 ） ,respectively. The principal toxic reactions were myelosuppression, nausea/vomiting,fatigue and alopeeia. Patients receiving pemetrexed were less likely to have neutropenia, than receiving doeetaxel （ 25.8% vs 51.4% , P 〈 0. 05 ）. Conclusion Pemetrexed plus eisplatin has the saute activity as docetaxel plus cisplatin in treatment of patients with advanced NSCLC. However, the latter is better tolerated by the patients.
出处
《武警医学》
CAS
2011年第6期495-497,500,共4页
Medical Journal of the Chinese People's Armed Police Force
关键词
培美曲塞
多西他赛
晚期非小细胞肺癌
pemetrexed
docetaxel
advanced non - small - （＇,ell lung cancer
